Loading...
XNAS
KPTI
Market cap49mUSD
Dec 05, Last price  
5.75USD
1D
-2.71%
1Q
-12.88%
Jan 2017
-38.83%
IPO
-64.02%
Name

Karyopharm Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:KPTI chart
P/E
—
P/S
0.34
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-33.39%
Rev. gr., 5y
28.85%
Revenues
145m
-0.55%
152,000634,000387,000229,000250,000154,0001,605,00030,336,00040,893,000108,085,000209,819,000157,074,000146,033,000145,237,000
Net income
-76m
L-46.60%
-10,311,000-15,888,000-33,947,000-75,777,000-118,181,000-109,577,000-128,984,000-178,407,000-199,590,000-196,273,000-124,088,000-165,291,000-143,099,000-76,422,000
CFO
-127m
L+37.49%
-8,549,000-15,509,000-30,290,000-51,447,000-94,029,000-84,391,000-73,717,000-159,117,000-190,822,000-160,234,000-107,116,000-149,554,000-92,723,000-127,486,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
URL
https://karyopharm.com/
IPO date
Nov 06, 2013
Employees
385
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT